ACADIA Pharmaceuticals logo

ACADIA PharmaceuticalsNASDAQ: ACAD

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

27 May 2004

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$2.44 B
-56%vs. 3y high
83%vs. sector
-24%vs. 3y high
86%vs. sector
-66%vs. 3y high
81%vs. sector
-72%vs. 3y high
45%vs. sector

Price

regular market | 6 min ago
$14.69+$0.19(+1.31%)

Dividend

No data over the past 3 years
$241.96 M$248.81 M
$241.96 M$33.39 M

Analysts recommendations

Institutional Ownership

ACAD Latest News

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
zacks.com30 October 2024 Sentiment: POSITIVE

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
businesswire.com17 October 2024 Sentiment: POSITIVE

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on November 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will be available on Acadia's website, Acadia.com under the investors section and will be archived.

Why Acadia (ACAD) Could Beat Earnings Estimates Again
zacks.com14 October 2024 Sentiment: POSITIVE

Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
businesswire.com23 September 2024 Sentiment: POSITIVE

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors. “We are excited to welcome Catherine Owen Adams as the new CEO of Acadia,” said Stephen Biggar, M.D., Ph.D., Chair of the Board of Directors. “Catherine is a proven global leader with a distinguished record of accomplishment of driving growth and innovation in the pharmaceutical indus.

Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?
zacks.com05 September 2024 Sentiment: POSITIVE

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues
zacks.com07 August 2024 Sentiment: POSITIVE

Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.

Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates
zacks.com06 August 2024 Sentiment: POSITIVE

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.01 per share a year ago.

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
zacks.com30 July 2024 Sentiment: NEUTRAL

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
zacks.com16 July 2024 Sentiment: POSITIVE

Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.

Acadia Pharmaceuticals: Back In The Buy Zone
seekingalpha.com23 June 2024 Sentiment: POSITIVE

Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to Nuplazid Phase 3 trial failure for schizophrenia. Despite setbacks, Acadia has strong financials with $470.5 million in cash and investments, and is trading at two times FY24 revenue net of cash. An updated analysis around Acadia Pharmaceuticals follows in the paragraphs below.

What type of business is ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals Inc. is an American biopharmaceutical company headquartered in San Diego, California, focused on the development and commercialization of innovative drugs for patients with central nervous system disorders. It was founded in 1993 as Receptor Technologies, Inc. The company commercializes the drug NUPLAZID (Pimavanserin), which was approved by the U.S. Food and Drug Administration (FDA) in April 2016 for the treatment of psychosis in Parkinson's disease (PD psychosis) and is the first and only drug approved in the U.S. for this condition. Additionally, the company continues to study the use of the drug for the treatment of other neurological and psychiatric disorders.

What sector is ACADIA Pharmaceuticals in?

ACADIA Pharmaceuticals is in the Healthcare sector

What industry is ACADIA Pharmaceuticals in?

ACADIA Pharmaceuticals is in the Biotechnology industry

What country is ACADIA Pharmaceuticals from?

ACADIA Pharmaceuticals is headquartered in United States

When did ACADIA Pharmaceuticals go public?

ACADIA Pharmaceuticals initial public offering (IPO) was on 27 May 2004

What is ACADIA Pharmaceuticals website?

https://www.acadia.com

Is ACADIA Pharmaceuticals in the S&P 500?

No, ACADIA Pharmaceuticals is not included in the S&P 500 index

Is ACADIA Pharmaceuticals in the NASDAQ 100?

No, ACADIA Pharmaceuticals is not included in the NASDAQ 100 index

Is ACADIA Pharmaceuticals in the Dow Jones?

No, ACADIA Pharmaceuticals is not included in the Dow Jones index

When was ACADIA Pharmaceuticals the previous earnings report?

No data

When does ACADIA Pharmaceuticals earnings report?

The next expected earnings date for ACADIA Pharmaceuticals is 06 November 2024